| Literature DB >> 16079085 |
Richard Y Wang1, Larry L Needham, Dana B Barr.
Abstract
The apparent decline in the age at puberty in the United States raises a general level of concern because of the potential clinical and social consequences of such an event. Nutritional status, genetic predisposition (race/ethnicity), and environmental chemicals are associated with altered age at puberty. The Exposure to Chemical Agents Working Group of the National Children's Study (NCS) presents an approach to assess exposure for chemicals that may affect the age of maturity in children. The process involves conducting the assessment by life stages (i.e., in utero, postnatal, peripubertal), adopting a general categorization of the environmental chemicals by biologic persistence, and collecting and storing biologic specimens that are most likely to yield meaningful information. The analysis of environmental samples and use of questionnaire data are essential in the assessment of chemicals that cannot be measured in biologic specimens, and they can assist in the evaluation of exposure to nonpersistent chemicals. Food and dietary data may be used to determine the extent to which nutrients and chemicals from this pathway contribute to the variance in the timing of puberty. Additional research is necessary in several of these areas and is ongoing. The NCS is uniquely poised to evaluate the effects of environmental chemicals on the age at puberty, and the above approach will allow the NCS to accomplish this task.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16079085 PMCID: PMC1280355 DOI: 10.1289/ehp.7615
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Human studies on the effects of environmental chemical exposure on pubertal development.
| Associated health effects
| ||||||
|---|---|---|---|---|---|---|
| Chemical | Reference | Developmental window or route of exposure assessed | Exposure measure | Level of exposure | Males | Females |
| Intrauterine | Milk level at birth | Median, 2.4 μg/g lipids
| No effect on attainment of puberty by DDE level from intrauterine exposure
| No effect on time of onset, height, or body weight at puberty by DDE level from intrauterine exposure | ||
| Postnatal (breastfeeding) | Lactational exposure index | No effect on attainment of puberty by DDE level from lactational exposure | ||||
| Puberty | Serum level at or postpuberty | Immigrant/adopted, 1.04 μg/L (median)
| Immigrant children with idiopathic precocious puberty had higher DDE levels than native children with precocious puberty; adoption status was not associated with DDE level | |||
| Dioxin-like compounds | Puberty | Serum level at puberty | Exposures: range of means, 0.11–0.21 ng TEQ/L | No effect on likelihood to attain either genital maturity or pubarche by TEQ level | Decreased likelihood to attain thelarche with increasing TEQ level | |
| Endosulfan | Puberty | Serum level at puberty | Exposed, 7.47 ± 1.19 μg/L (mean ± SD)
| Delayed pubarche and genital maturity with exposure | ||
| Lead | Puberty | Blood level at puberty | Non-Hispanic whites: geometric mean, 1.4 μg/dL; 95% CI, 1.2–1.5 | No effect on pubarche, menarche, or thelarche by lead level for non- Hispanic whites | ||
| African Americans: geometric mean, 2.1 μg/dL; 95% CI, 1.9–2.3 | Delayed pubarche, thelarche, and menarche with increasing lead level for African Americans | |||||
| Mexican Americans: geometric mean, 1.7 μg/dL, 95% CI, 1.6–1.9 | Delayed pubarche and thelarche with increasing lead level for Mexican Americans
| |||||
| Puberty | Blood level at puberty | Range, 0.7–21.7 μg/dL | Delayed pubarche and menarche with increasing lead level, no effect on attainment of thelarche by lead level | |||
| PBBs | Intrauterine | Extrapolated maternal serum level postevent | Mean ± SD, 17.3 μg/L ± 107.8; range, ND | Accelerated attainment of menarche with increasing intrauterine PBB level and breast-feeding | ||
| PCBs | Intrauterine | Maternal serum level postevent | Mean ± SD, 5.6 μg/L ± 5.5; range, ND | No effect on age at menarche or attainment of thelarche or pubarche by intrauterine PCB level | ||
| Puberty | Serum level at puberty | Exposures: range of PCB-138 means, 94–227 ng/L | Decreased likelihood to attain genital maturity with increasing PCB-138 level | No effect on likelihood to attain either thelarche or pubarche by PCB-138 level | ||
| Exposures: range of PCB-153 means, 166–332 ng/L | Decreased likelihood to attain pubarche with increasing PCB-153 level | No effect on likelihood to attain either thelarche or pubarche by PCB-153 level | ||||
| Exposures: range of PCB-180 means, 95–202 ng/L | No effect on likelihood to attain either genital maturity or pubarche by PCB-180 level | No effect on likelihood to attain either thelarche or pubarche by PCB-180 level | ||||
| Intrauterine | Milk level at birth | Median, 1.7 μg/g lipids,
| No effect on time of onset of puberty or height or body weight at puberty by PCB level from intrauterine exposure | No effect on time of onset of puberty by PCB level from intrauterine exposure
| ||
| Postnatal (breastfeeding) | Lactational exposure index | No effect on time of onset of puberty or height or body weight at puberty by PCB level from lactational exposure | No effect on time of onset, height, or body weight at puberty by PCB level from lactational exposure | |||
| Phthalates | Puberty | Serum level at puberty | Cases: DEHP, 450 μg/L (mean ± SD not given)
| Premature thelarche | ||
| Phytoestrogens | Puberty | Questionnaire | Use of soy-based formula increased likelihood for onset of premature thelarche before 2 years of age | |||
Abbreviations: DEHP, di-(2-ethylhexyl) phthalate; ND, not detected; p,p’-DDE, p,p', dichlorodiphenyldichloroethylene; TEQ, toxic equivalent.
PBB limit of detection, 1 μg/L.
Cows contaminated by feed containing PBB in 1973.
PCB limit of detection, 5 μg/L.
Sampling periods for the assessment of exposure to persistent and nonpersistent chemicals.
| Preconception | In utero | Perinatal | Postpartum (18–24 months) | Prepuberty (5–6 years) | Midpuberty | Postpuberty | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Persistent chemicals | |||||||||||
| Urine | M/F | M (10–15 weeks | M | x | x | x | x | ||||
| Serum | M/F | M (10–15 weeks | M | x | x | x | x | ||||
| Whole blood | M/F | M (10–15 weeks | M | x | x | x | x | ||||
| Hair | M | ||||||||||
| Human milk | 2 weeks – 2 months postpartum | ||||||||||
| Cord serum | x | ||||||||||
| Cord whole blood | x | ||||||||||
| Meconium | x | ||||||||||
| Dietary assessment | x | M (10–15 weeks | x | x | x | x | x | ||||
| Home air sample | x | x | x | x | x | x | x | ||||
| Home composite dust sample | x | x | x | x | x | x | x | ||||
| Other environmental samples | Special studies | Special studies | Special studies | Special studies | Special studies | Special studies | Special studies | ||||
| Questionnaire | x | x | x | —— At 6, 12, 24 and 36 months, then annually until puberty —— | |||||||
| Ecologic analysis (e.g., GIS) | x | x | x | x | x | x | x | ||||
| Nonpersistent chemicals | |||||||||||
| Urine | M/F | M (10–15 weeks | M | x | x | x | x | ||||
| Serum | M/F | M (10–15 weeks | M | x | x | x | x | ||||
| Human milk | 2 weeks – 2 months postpartum | ||||||||||
| Cord serum | x | ||||||||||
| Meconium | x | ||||||||||
| Dietary assessment | x | M (10–15 weeks | x | x | x | x | x | ||||
| Home air sample | x | x | x | x | x | x | x | ||||
| Home composite dust sample | x | x | x | x | x | x | x | ||||
| Other environmental samples | Special studies | Special studies | Special studies | Special studies | Special studies | Special studies | Special studies | ||||
| Questionnaire | x | x | x | —— At 6, 12, 24 and 36 months, then annually until puberty —— | |||||||
| Ecologic analysis (e.g., GIS) | x | x | x | x | x | x | x | ||||
GIS, geographic information system; F, father; M, mother; x, period when samples are to be collected.
At the time of enrollment.
Media with extant laboratory methods for likely target chemical agent. Note that for nonpersistent chemicals, multiple samples of biologic specimens may be needed during this time because of possible variability in biologic exposure level due to the short half-life of the chemical. This is particularly important if a critical exposure period is being considered. Alternatively, pilot data may demonstrate the lack of need for frequent sampling if constant exposure occurred in a stable environment.
Timed specimen collection; morning void specimen with creatinine measurement.
Pediatric urine bag or diaper sample for non-toilet-trained children. If not diaper, spot samples or multiple spots.
For example, weeks 10–15 of gestation are a critical period for breast development.
When blood collection is at a young age, piggyback on lead screen at 12 and 24 months that is recommended by the Centers for Disease Control and Prevention.
Environmental sampling, dietary assessment, questionnaires, and ecologic analysis are necessary for persistent chemicals to determine either route or pathway of exposure; otherwise, exposure can be established through the analysis of biologic specimens. Information should be obtained proximate to the sampling period for biologic specimens.
Health effect measures to assess for pubertal development.a
| Onset of puberty |
| Sexual maturity rating (Tanner staging) |
| Performed by observer or by self-reporting |
| Frequency: annually |
| Stature |
| Hormones [luteinizing hormone, estradiol, testosterone, dehydroepiandrostendione-sulfate (DHEA-S)] |
| Salivary hormone levels |
| Thyroid-stimulating hormone |
| Later stages of puberty |
| Voice pattern change (males) |
| Menarche |
| Menstrual history |
| Dual-energy X-ray absorptiometry |
| At age 6 and 12 years for females and at age 6 and 14 years for males |
Discussed at the NCS inter-work group meeting “Obesity and Physical Development.” This meeting was co-chaired by the Nutrition, Growth, and Pubertal Development and the Exposure to Chemical Agents working groups in Baltimore, Maryland (USA), on 17–18 December 2002.
Potential risk factors affecting pubertal development.
| Precocious |
| Gonadotropin-dependent (central precocious puberty) |
| Brain pathology (e.g., hypothalamic hamartoma, tumors, hydocephalus, severe head trauma) |
| Hypothyroidism, untreated |
| Gonadotropin-independent precocious puberty |
| McCune-Albright syndrome in girls |
| Familial male precocious puberty (testotoxicosis) |
| Tumors (ovarian, adrenocortical, Leydig cell, chorionic gonadotropin-secreting tumors) |
| Exogenous pharmaceutical estrogen or androgen use |
| Isolated premature thelarche, premature pubarche/adrenarche, premature menarche |
| Delayed |
| Poor nutrition |
| Chronic illness |
| Constitutional growth delay |
| Intense physical training |
| General categories associated with altered pubertal development |
| General nutrition |
| General health |
| Brain injury |
| Obesity |
| Socioeconomic status |
| Immigration/adoption |
| Race/ethnicity |
| Pharmaceuticals [estrogenic, androgenic, estrogen blocker (i.e., aromatase inhibitors), and androgen blocker (e.g., finasteride, flutamide)] |
| Genetics |
| Gestational age |